Skip to main content
Skip to main content
Go to homepage

PBTC 039 - Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma

Description:

For complete information, please visit the study on clinicaltrials.gov

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:
Closed
Full IRB Study Title:
PBTC-039: Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Un-resectable or Recurrent Craniopharyngioma - Cincinnati
IRB Study ID:
141110
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.